Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins. NHS England ...

Demand for NHS Talking Therapies has reached an all-time high. The service received 1.82 million referrals in 2023/24. This is slightly higher than 2021/2022, and more than double the 884,000 received ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

A list of downloadable documents created during development.

The draft guidance, which is open for public consultation until 22 October, does not recommend elacestrant for treating oestrogen receptor-positive, human epidermal growth factor receptor 2-negative ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

In this episode, we hear from Professor Jonathan Benger, NICE's deputy chief executive and interim director of our Centre for Guidelines. He's joined by Dr Bryony Kendall who is a GP and sits on NICE ...

Dear stakeholders, For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) ...

Latanoprost–netarsudil is recommended as an option for reducing intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension when a prostaglandin analogue alone has not ...

Suggested remit: To appraise the clinical and cost effectiveness of iptacopan within its marketing authorisation for treating complement 3 (C3) glomerulopathy.